Literature DB >> 18286688

Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy.

Christiane Jakob1, Torsten Liersch, Wolfdietrich Meyer, Heinz Becker, Gustavo-B Baretton, Daniela-E Aust.   

Abstract

AIM: To investigate the predictive value of Ki67 and p53 and their correlation with thymidylate synthase (TS) gene expression in a rectal cancer patient cohort treated according to a standardized recommended neoadjuvant treatment regimen.
METHODS: Formalin fixed, paraffin embedded pre-therapeutical tumor biopsies (n = 22) and post-therapeutical resection specimens (n = 40) from patients with rectal adenocarcinoma (clinical UICC stage II/III) receiving standardized neoadjuvant 5-fluorouracil (5-FU) based chemoradiotherapy were studied for Ki67 and p53 expression by immunohistochemistry and correlated with TS mRNA expression by quantitative TaqMan real-time PCR after laser microdissection. The results were compared with histopathological tumor regression according to a standardized semiquantitative score grading system.
RESULTS: Responders (patients with high tumor regression) showed a significantly lower Ki67 expression than non-responders in the pre-therapeutical tumor biopsies (81.2% vs 16.7%; P < 0.05) as well as in the post-therapeutical resection specimens (75.8% vs 14.3%; P < 0.01). High TS mRNA expression was significantly correlated with a high Ki67 index and low TS mRNA expression was significantly correlated with a low Ki67 index in the pre-therapeutical tumor biopsies (corr. coef. = 0.46; P < 0.01) as well as in the post-therapeutical resection specimens (corr. coef. = 0.40; P < 0.05). No significant association was found between p53 and TS mRNA expression or tumor regression.
CONCLUSION: Ki67 has, like TS, predictive value in rectal cancer patients after neoadjuvant 5-FU based chemoradiotherapy. The close correlation between Ki67 and TS indicates that TS is involved in active cell cycle processes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18286688      PMCID: PMC2689409          DOI: 10.3748/wjg.14.1060

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  41 in total

1.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

Authors:  D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

2.  Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer.

Authors:  B van Triest; H M Pinedo; J L Blaauwgeers; P J van Diest; P S Schoenmakers; D A Voorn; K Smid; K Hoekman; H F Hoitsma; G J Peters
Journal:  Clin Cancer Res       Date:  2000-03       Impact factor: 12.531

3.  p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.

Authors:  T Hashimoto; Y Tokuchi; M Hayashi; Y Kobayashi; K Nishida; S Hayashi; Y Ishikawa; S Tsuchiya; K Nakagawa; J Hayashi; E Tsuchiya
Journal:  Cancer Res       Date:  1999-11-01       Impact factor: 12.701

4.  Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines.

Authors:  Weiguang Wang; Howard L McLeod; James Cassidy
Journal:  Int J Cancer       Date:  2003-04-20       Impact factor: 7.396

5.  p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.

Authors:  Reiping Tang; Jeng-Yi Wang; Chung-Wei Fan; Kuo-Chien Tsao; Hong-Hua Chen; Chi-Ming Wu; Jinn-Shiun Chen; Chung Rong Changchien; Ling-Ling Hsieh
Journal:  Cancer Lett       Date:  2004-07-08       Impact factor: 8.679

Review 6.  Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis.

Authors:  Sanjay Popat; Athena Matakidou; Richard S Houlston
Journal:  J Clin Oncol       Date:  2004-02-01       Impact factor: 44.544

7.  Prognostic value of P53 mutations in rectal carcinoma.

Authors:  Christine Rebischung; Jean-Pierre Gérard; Jacqueline Gayet; Gilles Thomas; Richard Hamelin; Pierre Laurent-Puig
Journal:  Int J Cancer       Date:  2002-07-10       Impact factor: 7.396

8.  Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.

Authors:  John Boyer; Estelle G McLean; Somaiah Aroori; Peter Wilson; Andrea McCulla; P Declan Carey; Daniel B Longley; Patrick G Johnston
Journal:  Clin Cancer Res       Date:  2004-03-15       Impact factor: 12.531

9.  Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer.

Authors:  S Kamoshida; M Suzuki; R Shimomura; Y Sakurai; Y Komori; I Uyama; Y Tsutsumi
Journal:  Br J Cancer       Date:  2007-01-09       Impact factor: 7.640

10.  Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients.

Authors:  A Paradiso; G Simone; S Petroni; B Leone; C Vallejo; J Lacava; A Romero; M Machiavelli; M De Lena; C J Allegra; P G Johnston
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

View more
  27 in total

Review 1.  Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer.

Authors:  Takashi Akiyoshi; Takashi Kobunai; Toshiaki Watanabe
Journal:  Surg Today       Date:  2012-06-16       Impact factor: 2.549

2.  Tumor Heterogeneity as a Predictor of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.

Authors:  Alissa Greenbaum; David R Martin; Thèrése Bocklage; Ji-Hyun Lee; Scott A Ness; Ashwani Rajput
Journal:  Clin Colorectal Cancer       Date:  2019-02-13       Impact factor: 4.481

3.  Imunoexpression of Ki-67 and p53 in rectal cancer tissue after treatment with neoadjuvant chemoradiation.

Authors:  Nara Rosana Andrade; Celina Tizuko Fujiyama Oshima; Thiago Simão Gomes; Ricardo Artigiani Neto; Nora Manoukian Forones
Journal:  J Gastrointest Cancer       Date:  2011-03

Review 4.  Molecular Biology: Are We Getting Any Closer to Providing Clinically Useful Information?

Authors:  Georgios Karagkounis; Matthew F Kalady
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

5.  Gender-related differences in pathological and clinical tumor response based on immunohistochemical proteins expression in rectal cancer patients treated with short course of preoperative radiotherapy.

Authors:  Anna Gasinska; Agnieszka Adamczyk; Joanna Niemiec; Beata Biesaga; Zbigniew Darasz; Jan Skolyszewski
Journal:  J Gastrointest Surg       Date:  2014-04-23       Impact factor: 3.452

6.  Predictive markers of chemoradiotherapy for rectal cancer: comparison of biopsy specimens taken before and about 1 week after the start of chemoradiotherapy.

Authors:  Toshiyuki Suzuki; Sotaro Sadahiro; Akira Tanaka; Kazutake Okada; Gota Saito; Akemi Kamijo; Takeshi Akiba; Shuichi Kawada
Journal:  Int J Clin Oncol       Date:  2015-04-02       Impact factor: 3.402

Review 7.  The role of capecitabine in locally advanced rectal cancer treatment: an update.

Authors:  Carlos Fernández-Martos; Miquel Nogué; Paloma Cejas; Víctor Moreno-García; Ana Hernández Machancoses; Jaime Feliu
Journal:  Drugs       Date:  2012-05-28       Impact factor: 9.546

8.  p27 expression in post-treatment rectal cancer: a potential novel approach for predicting residual nodal disease.

Authors:  Tobias Leibold; Vanessa W Hui; Jinru Shia; Jeannine A Ruby; Elyn R Riedel; José G Guillem
Journal:  Am J Surg       Date:  2014-04-13       Impact factor: 2.565

9.  Chromosomal copy number changes of locally advanced rectal cancers treated with preoperative chemoradiotherapy.

Authors:  Marian Grade; Jochen Gaedcke; Danny Wangsa; Sudhir Varma; Jaje Beckmann; Torsten Liersch; Clemens Hess; Heinz Becker; Michael J Difilippantonio; Thomas Ried; B Michael Ghadimi
Journal:  Cancer Genet Cytogenet       Date:  2009-08

10.  Antidepressants increase neural progenitor cells in the human hippocampus.

Authors:  Maura Boldrini; Mark D Underwood; René Hen; Gorazd B Rosoklija; Andrew J Dwork; J John Mann; Victoria Arango
Journal:  Neuropsychopharmacology       Date:  2009-07-15       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.